Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🇫🇮 FI Market
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Healthcare
Any
Automobiles
Banks
Capital Goods
Commercial Services
Consumer Durables
Consumer Services
Diversified Financials
Energy
Consumer Retailing
Food, Beverage & Tobacco
Healthcare
Household
Insurance
Materials
Media
Pharmaceuticals & Biotech
Real Estate
Retail
Semiconductors
Software
Tech
Telecom
Transportation
Utilities
Create a narrative
Community
/
Finland
/
Healthcare
Healthcare Finnish Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Healthcare Finnish Investing Ideas
All companies
Popular
Undervalued
Overvalued
Terveystalo Oyj
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Kela 65 Scheme And Digital Health Will Broaden Patient Access
Key Takeaways Expansion into new public and private healthcare initiatives, as well as high-demand segments, positions the company for sustainable revenue growth and margin enhancement. Accelerated digital transformation and operational efficiencies, alongside strategic M&A, support improved cost structure and increased share of higher-margin services.
View narrative
€12.76
FV
17.2% undervalued
intrinsic discount
2.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
3 days ago
author updated this narrative
Modulight Oyj
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
US Expansion And R&D Pipeline Will Build Future Opportunity
Key Takeaways Geographical expansion and a focus on mature R&D projects are key drivers of future revenue growth and increased demand, especially in the U.S. New patent protections and a shift to a service-based model in high-value applications could enhance competitive advantage and long-term earnings stability. Delays, geopolitical risks, and business model transition challenges affect Modulight's revenue predictability, production efficiency, and pose potential risks to future growth and margins.
View narrative
€1.85
FV
35.4% undervalued
intrinsic discount
31.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
3 days ago
author updated this narrative
Nightingale Health Oyj
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
New US And Singapore Labs Will Improve Healthcare Efficiency
Key Takeaways Nightingale Health's innovative disease detection from a single blood sample and international deals could boost global market penetration and revenue expansion. Strategic vertical integration, low burn rate, and possible stock listings aim to enhance operational efficiency, financial stability, and investor interest.
View narrative
€2.90
FV
18.3% undervalued
intrinsic discount
50.78%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
3 days ago
author updated this narrative
Revenio Group Oyj
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Advanced Imaging And Tonometer Devices Will Expand Global Markets
Key Takeaways Strong growth in imaging and tonometer business across key regions, with promising future revenue driven by demand and a robust sales pipeline. Product approvals and new screening solutions are expected to enhance revenue and margins through increased adoption and recurring licensing streams.
View narrative
€30.46
FV
20.2% undervalued
intrinsic discount
11.80%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
12 days ago
author updated this narrative
Value any company in seconds
Popular companies